The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 401–500 of 721
Agnorelli, C., Cinti, A., Barillà, G., Lomi, F., Scoccia, A., Benelli, A., Neri, F., Smeralda, C. L., Cuomo, A., Santarnecchi, E., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02889-2 · Cited by 17
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
Ryan, R. S., Copello, A. G., & Fox, A. P. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04628-9 · Cited by 17
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
“…2017; Nichols et al., 2017b; Os ´ orio et al., 2015; Palhano-Fontes et al., 2019; Roseman et al., 2018; Ross et al., 2016; Sanches et al., 2016; Vollenweider and Kometer, 2010), clinical anxiety and/or depression (Muttoni et al., 2019), and may provide therapeutic relief longer (Carhart-Harris…”
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 18
“This enhanced neuroplasticity is attributed to their postsynaptic effects in the medial prefrontal cortex, speci fi cally in the fi fth layer, where they stimulate glutamate release and activate a -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (11).”
BackgroundAghajanian, S., Shafiee, A., Omran, S. P., Nejad, A. R., Jafarabady, K., Gargari, O. K., Firouzabadi, S. R., Mohammadi, I., Babaheidari, T. B., & Bakhtiyari, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241287542 · Cited by 15
“A reduction in the expression of BDNF is involved in behavioral phenomena associated with depression (Dwivedi, 2009), and BDNF release is believed to be a common, convergent down-stream mechanism of pharmacologic agents that alleviate depression (Duman et al., 2021).”
Pekala, R. J., & Creegan, K. (2020) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2002019 · Cited by 14
Improving mental health care in depression: A call for action
Eder, J., Dom, G., Gorwood, P. A. P. M., Kärkkäinen, H., Decraene, A., Kumpf, U., Beezhold, J., Samochowiec, J., Kurimay, T., Gäebel, W., et al. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2434 · Cited by 20
“The anesthetic ketamine is also a hallucinogen in the broader sense, although it affects the glutamatergic system via the N-methyl-D-aspartate receptor [46].”
BackgroundMicrodosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 16
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Exploring the effect of microdosing psychedelics on creativity in an open-label natural settingPreprint
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchař, M., Sjoerds, Z., & Hommel, B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/384412 · Cited by 12
A Systematic Study of Microdosing PsychedelicsPreprint
Polito, V., & Stevenson, R. J. (2018) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/cw9qs · Cited by 13
Classic psychedelics: the special role of the visual system
Császár-Nagy, N., Kapócs, G., & Bókkon, I. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0092 · Cited by 14
“During the past 10 years, there have been increasing interests again in the potential clinical uses of these classic hallucinogens for the treatment of anxiety, depression, addictions, and various behavioral health conditions (Vollenweider and Kometer, 2010; Grob et al., 2011; Gasser et al., 2014; Bogenschutz and John…”
BackgroundGao, B., Qu, Y.-C., Cai, M., Zhang, Y.-Y., Lu, H., Li, H.-X., Tang, Y., & Shen, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.006 · Cited by 12
Mathai, D. S., Hilbert, S. N., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia‐Romeu, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0035 · Cited by 14
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
A continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
“…the case of ketamine distorted sense of self and thought, as well as experiences of dissociation (Krystal et al., 1994), whereas the effects of psychedelics are more perceptual but can also include experiences of distorted thinking (GouzoulisMayfrank et al., 1998; Vollenweider and Kometer, 2010).”
BackgroundInfluentialBioactive Alkaloids from Fungi: Psilocybin
Mahmood, Z. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_19 · Cited by 17
Altered States: Psychedelics and Anesthetics
Icaza, E. E., & Mashour, G. A. (2013) · Anesthesiology · doi:10.1097/01.anes.0000435635.42332.ee · Cited by 15
Pesarico, A. P., Rosa, S. G., Stangherlin, E. C., Mantovani, A. C., Zeni, G. R., & Nogueira, C. W. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.01.013 · Cited by 11
“However, limitations of these drugs have been pointed out (Fava, 2003) and novel targets have been implicated in the etiology of depression (Skolnick et al., 2009; Vollenweider and Kometer, 2010), such as the glutamatergic and gamma-aminobutyric acid (GABA)ergic systems (Krystal et al.”
BackgroundBuchborn, T., Lyons, T., Song, C., Feilding, A., & Knöpfel, T. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120903465 · Cited by 13
“…activating serotonin 2A receptors (5-HT2ARs) (Kraehenmann et al., 2017; Preller et al., 2017), with glutamatergic pyramidal cells within the cerebral cortex proposed as one of the key sites of their action (Marek, 2017; Muthukumaraswamy et al., 2013; Nichols, 2016; Vollenweider and Kometer, 2010).”
BackgroundDrogen- und Medikamentenabhängigkeit
Kienast, T., Heinz, A., & Soyka, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_50 · Cited by 11
Mueller, M. J., Aicher, H., Dornbierer, D., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf001 · Cited by 14
Symptoms and Neurobiological Models of Language in Schizophrenia
Nagels, A., & Kircher, T. T. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-407794-2.00071-7 · Cited by 14
Functional associations among G protein-coupled neurotransmitter receptors in the human brain
Janušonis, S. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-16 · Cited by 15
“disorders [63,65,66].”
Rational Suicide in the Elderly
Balasubramaniam, M., & McCue, R. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6 · Cited by 10
Bottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 15
Modulatory Effects of Ketamine and Lamotrigine on Cognition: Emotion Interaction in the Brain
Gärtner, M., Weigand, A., Keicher, C., Meiering, M. S., Weigner, D., Carstens, L., Hertrampf, R., Beckmann, C. F., Mennes, M., Wunder, A., et al. (2023) · Neuropsychobiology · doi:10.1159/000528315 · Cited by 12
The Resurgence of Hallucinogen Drugs in Clinical Research
Rivera-Garcia, M. T., & Cruz, S. L. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000108 · Cited by 16
“Glutamate activates pyramidal neurons in the prefrontal cortex (PFC) that send their projections to the Raphe Nucleus and stimulate serotonergic neurons, which, in turn, send projections back to the PFC where serotonin directly activates 5-HT 2A receptors 26 .”
BackgroundTearavarich, R., Hahnvajanawong, V., Dempster, N. M., Daley, P. F., Cozzi, N. V., & Brandt, S. D. (2010) · Drug Testing and Analysis · doi:10.1002/dta.223 · Cited by 10
Colosimo, F. A., Borsellino, P., Krider, R. I., Márquez, R., & Vida, T. A. (2024) · Psychoactives · doi:10.3390/psychoactives3010007 · Cited by 11
“DMT and psilocybin share a similar main mechanism of action, binding on 5-HT 2A receptors [189–191], and DMT’s exploratory studies showed subjective effects similar to a significant psychedelic experience in the higher dose group [92,140].”
BackgroundHealy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 11
“…selflessness, self-transcendence, or “ ego dissolution, ” frequently leading to enduring positive changes in mood, personality, and self-concept (Griffiths et al., 2018; Letheby and Gerrans, 2017; MacLean et al., 2011; Milli ` ere et al., 2018; Vollenweider and Kometer, 2010; Amada et al., 2020).”
Castanheira, S., Gomes, C. V., Bicker, J., & Fortuna, A. C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104371 · Cited by 11
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Silva, S. R. B., Pantrigo, É. J., Medina, M., Arichelle, F., de Almeida, R. N., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.002 · Cited by 11
Becker, R., Gass, N., Kußmaul, L., Schmid, B., Scheuerer, S., Schnell, D., Dorner‐Ciossek, C., Weber‐Fahr, W., & Sartorius, A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05310-3 · Cited by 11
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Self-citationA role for enhanced functions of sleep in psychedelic therapy?
Froese, T., Leenen, I., & Páleníček, T. (2018) · Adaptive Behavior · doi:10.1177/1059712318762735 · Cited by 8
“Vollenweider and Kometer (2010) proposed that the antidepressant effects of psilocybin are based on the modulation of the neural circuits implicated in mood and affective disorders and that the reduction in symptoms outlasts the acute effects due to glutamate-dependent neuroplastic adaptation.”
BackgroundDiéguez, S. (2016) · Cerveau & Psycho · doi:10.3917/cerpsy.074.0094 · Cited by 9
Junges, L. H., & Müller‐Santos, M. (2024) · Biotechnology Progress · doi:10.1002/btpr.3513 · Cited by 10
“23,24 The psychotropic effects caused by Psilocybe sp. mushrooms consumption have been known for thousands of years by many pre-Columbian Mesoamerican cultures, and they were used to induce altered states of consciousness in healing rituals and religious ceremonies.”
Hu, S., Lin, C., Wang, H., & Wang, X. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00094 · Cited by 9
Empirische Untersuchung veränderter Bewusstseinszustände
Schmidt, T. T., & Majić, T. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_65 · Cited by 9
Carbone, C., Adinolfi, A., Cinque, S., Lacivita, E., Alleva, E., Leopoldo, M., & Adriani, W. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12812 · Cited by 9
Harms, A. (2021) · Anthropology of Consciousness · doi:10.1111/anoc.12130 · Cited by 12
“…affects during ceremonies, might be considered more profound in psychedelic substance use, given the degree of suggestibility (Tart 1969; Robin L. Carhart-Harris et al. 2015) or neuroplasticity (Vollenweider and Kometer 2010; Frecska, Bokor, and Winkelman 2016) instilled by psychedelics.”
BackgroundThe Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 10
Research on psychedelic substances
Brandt, S. D., & Passie, T. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1389 · Cited by 8
Back to the future: Research renewed on the clinical utility of psychedelic drugs
Lieberman, J. A., & Shalev, D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675755 · Cited by 11
“…5-HT-2A receptors (Nichols, 2016), which is believed to produce subjective effects of perceptual disturbances, sensations of spiritual oneness or mystical ecstasy, and, at times, paranoia or anxiety (Vollenweider and Kometer, 2010), the mechanism mediating such effects is incompletely understood.”
BackgroundInfluentialTreatment approaches and efficacy in psychedelic-induced psychosis: A systematic review
Sulstarova, A., Scheuerlein, L., Monari, S., Seragnoli, F., Thorens, G., Preller, K. H., Böge, K., Sentissi, O., Kaiser, S., Solmi, M., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104604 · Cited by 7
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 10
Wizła, M., Kraus, S. W., & Lewczuk, K. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152303 · Cited by 9
Psychedelic-assisted therapy for people with gambling disorder?
Romero, P., Czakó, A., van den Brink, W., & Demetrovics, Z. (2024) · Journal of Behavioral Addictions · doi:10.1556/2006.2024.00004 · Cited by 10
“…of psychedelics are supposed to be mediated through their interaction with serotonin 5-HT2A receptors in the brain, leading to a cascade of neural effects that may facilitate therapeutic insights and promote emotional processing in individuals with mental disorders (Vollenweider & Kometer, 2010).”
BackgroundPsychedelic intimacy: Altered states of consciousness in romantic relationships
Neubert, J. J., Anderson, K., & Mason, N. L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00319 · Cited by 12
The zebrafish for preclinical psilocybin research
Syed, O. A., Tsang, B., & Gerlai, R. T. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105381 · Cited by 9
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6
Gao, Z., Winhusen, T. M., Gorenflo, M. P., Dorney, I., Ghitza, U. E., Kaelber, D. C., & Xu, R. (2024) · Addiction · doi:10.1111/add.16715 · Cited by 8
Wachełko, O., Nowak, K., Tusiewicz, K., Zawadzki, M., & Szpot, P. (2024) · The Analyst · doi:10.1039/d4an01361a · Cited by 6
Psychedelics, attachment, and enculturation dynamics: Prospects and challenges
Cassidy, E. K., Dupuis, D., Timmermann, C., & Granqvist, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00459 · Cited by 8
Ulisse, K., Albitar, J., Aromin, J. T., & Berry, J. H. (2025) · Brain Sciences · doi:10.3390/brainsci15090980 · Cited by 9
“At a neurotransmitter level, classical psychedelics act as agonists to serotonin 5-HT 2 A receptors, initiating a neural cascade that augments emotional processing and psychological insight [119,120].”
Kupriyanova, O. V., Shevyrin, V. A., & Shafran, Y. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3232 · Cited by 7
Shamabadi, A., Ahmadzade, A., Aqamolaei, A., Mortazavi, S. H., Hasanzadeh, A., & Akhondzadeh, S. (2022) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v17i3.9733 · Cited by 10
“alters the signal transduction pathway involved in neural plasticity (15, 84-86).”
BackgroundPsychedelika in der Psychiatrie – Entwicklungen und die Stellung in Deutschland
Herwig, U., Mertens, L. J., Rosal, S. P., Koller, G., Jungaberle, A., Borgwardt, S., & Gründer, G. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1981-3152 · Cited by 7
“Es weist ebenfalls qualitativ be-wusstseinsmodulierende Eigenschaften auf und kann zu dissozia-tiven aber auch komplexen sensorischen Phänomenen sowie dem möglichen Erleben von Ego-desintegration und ozeanischer Entgren-zung führen [16].”
BackgroundThe Key Role of Intracellular 5-HT2A Receptors: A Turning Point in Psychedelic Research?
Sapienza, J. (2023) · Psychoactives · doi:10.3390/psychoactives2040018 · Cited by 7
“Classic (or serotonergic) psychedelics (semi-synthetics or derived from plants) are so called because their pharmacological effects are primarily mediated by the serotonergic system, as they are agonists or partial agonists of the 5-HT2A receptor [19,20].”
Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?
Postránecká, Z., Vejmola, Č., & Tylš, F. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.003 · Cited by 7
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 9
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00211 · Cited by 13
“Unlike ketamine, psilocybin has a low potential for addiction and toxicity (Gable, 2004), and has not been associated with long-term perceptual or neurological dysfunction (Studerus, Kometer, Hasler, & Vollenweider, 2010).”
BackgroundLópez‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.990405 · Cited by 7
“Psychedelic effects include an altered state of consciousness characterized by distortions of perception, hallucinations, visions, dissolution of self -boundaries and “the experience of union with the world” (11).”
BackgroundHigh-resolution spatiotemporal analysis of single serotonergic axons in an in vitro system
Hingorani, M., Viviani, A. M. L., Sanfilippo, J. E., & Janušonis, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.994735 · Cited by 8
“It may explain the profound effects of 5-HT-like psychedelics in mental disorders (Vollenweider and Kometer, 2010; Daws et al., 2022).”
BackgroundGold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
Vejmola, Č., Šíchová, K., Syrová, K., Janečková, L., Koudelka, V., Tesař, M., Nikolič, M., Viktorinová, M., Tylš, F., Korčák, J., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100524 · Cited by 8
“Psilocybin was administered orally at 0.26 mg/kg [equivalent to a full-hallucinogenic high dose (27,28)] using 1 mg and 5 mg capsules prepared at the Institute of Clinical and Experimental Medicine, Prague.”
InfluentialKetamine’s Therapeutic Role in Substance Use Disorders: A Narrative Review
Thomas, A., & Chambers, R. A. (2025) · NeuroSci · doi:10.3390/neurosci6030083 · Cited by 9
“Ketamine’s effects on altering or increasing extracellular glutamate levels may also therapeutically benefit corticolimbic system connectivity disruptions that keep patients stuck in SUDs [24,25].”
da Costa, S. C., Bormann, N. L., Oesterle, T., McGinnis, M. T., Ho, M., Vettleson-Trutza, S. A., Rummans, T. A., & Gold, M. S. (2025) · Brain Sciences · doi:10.3390/brainsci15101056 · Cited by 10
“Besides serotonergic effects, psychedelic drugs seem to engage dopamine D2 receptors, kappa opioid receptors, and monoamine oxidase enzymes, and influence monoamine transmission via modulation of serotonergic, dopaminergic, and noradrenergic transporters [24,33].”
Levinstein, M. R., Schoenborn, I., Manza, P., Schatzberg, A. F., Zarate, C. A., Bonaventura, J., & Michaelides, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.021 · Cited by 6
Vollebregt, R., Storm, A. E. M., Lucassen, P. J., & Somers, M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106529 · Cited by 11
Impact of psychedelics on craving in addiction: A systematic review
Chapron, S., Bonazzi, G., Lodovico, L. D., de Ternay, J., Landmann, C., Nourredine, M., Salvo, F., Sessa, B., Das, R., Rolland, B., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241308613 · Cited by 7
“…(Johnson et al., 2019; Nichols, 2016), whereas others underline their shared patterns of subjective experiences and downstream pharmacological effects (Garcia-Romeu et al., 2016; Kadriu et al., 2021; Krupitsky and Grinenko, 1997; Ly et al., 2018; Schenberg, 2018; Vollenweider and Kometer, 2010).”
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Timmermann, C. (2025) · Imaging Neuroscience · doi:10.1162/imag_a_00541 · Cited by 5
“Crucially, the investigation of the neural underpinning of one’s sense of self has been catalyzed via the timely re-introduction of psychedelic substances in human neuroscience research ( R. L. Carhart-Harris et al., 2012; McCulloch et al., 2022; Vollenweider & Kometer, 2010).”
Dimkov, P. R. (2018) · Journal of Genius and Eminence · doi:10.18536/jge.2018.04.3.1.07 · Cited by 10
Neural Correlates of Psychosis and Gender Dysphoria in an Adult Male
Schwarz, K., Fontanari, A. M. V., Mueller, A., Soll, B. M. B., da Silva, D. C., Salvador, J., Zucker, K. J., Schneider, M. A., & Lobato, M. I. R. (2015) · Archives of Sexual Behavior · doi:10.1007/s10508-015-0660-8 · Cited by 6
Animal Models and Hallucinogenic Drugs
Kozlenkov, A., & González‐Maeso, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4121-2_14 · Cited by 6
SANTOS, R. G. D. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000028 · Cited by 5
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2022) · medRxiv · doi:10.1101/2022.10.31.22281688 · Cited by 5
Psilocybin therapy for depression. A good trip?
Rucker, J. (2023) · Journal of Mental Health · doi:10.1080/09638237.2023.2183492 · Cited by 5
“Intriguingly, psilocybin and ketamine exert similar influences by an allied mechanism that converges on a large a surge of glutamate in the prefrontal cortex, and various downstream BDNF dependent changes to neural growth and synapse formation (Vollenweider & Kometer, 2010; Ly et al., 2020).”
BackgroundPsilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4242829/v1 · Cited by 5
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006 · Cited by 14
“To close the circle, 5- HT2A-R stimulation, subsequent glutamate release and AMPA receptor activation ( Lowe et al., 2021 ) activate the BDNF-associated TrkB and mTORC1 pathway which promotes BDNF expression itself ( Duman et al., 2016 ; Vollenweider and Kometer, 2010 ).”
Beaussant, Y., Tarbi, E. C., Nigam, K. B., Miner, S. A., Sager, Z. S., Sanders, J. J., Ljuslin, M., Guérin, B., Sholevar, R., Roddy, K., et al. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.10.010 · Cited by 4
Acute DOI treatment evokes dose and species-dependent locomotor effects on the elevated plus maze
Tiwari, P., & Vaidya, V. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111558 · Cited by 4
The immunomodulatory effects of psychedelics in Alzheimer’s disease-related dementia
Hosseini, A. M., Khaleghzadeh‐Ahangar, H., & Rahimi, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.062 · Cited by 4
Microglial phagocytosis and regulatory mechanisms: Key players in the pathophysiology of depression
Wang, M., Jin, G., Duan, T., Li, R., Gao, Y., Yu, M., & Xu, Y. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110383 · Cited by 8
Cognitive and affective models of psychedelics in rodents
Anderson, D., & Robinson, E. S. J. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.002 · Cited by 3
The mind’s abyss: Exploring the adverse effects of distinct forms of meditation
Szaszkó, B., & Tran, U. S. (2025) · Academia Mental Health and Well-Being · doi:10.20935/mhealthwellb7666 · Cited by 8
Jylkkä, J., Väyrynen, H., Lin, E., Walldén, C., Krabbe, A., Kähönen, J., & Sikka, P. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103901 · Cited by 8
Chaïb, S., Bouillot, C., Bouvard, S., Vidal, B., Zimmer, L., & Levigoureux, E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1213941 · Cited by 5
Ilyin, N. P., Nabiullin, A. D., Kozlova, A. D., Kupriyanova, O. V., Shevyrin, V. A., Gloriozova, T. A., Filimonov, D. A., Lagunin, A. A., Galstyan, D. S., Kolesnikova, T. O., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00017 · Cited by 5
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Tal, T. B., Pogodin, I., Botvinnik, A., Lifschytz, T., Heresco‐Levy, U., & Lerer, B. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03428-x · Cited by 4
“Psilocin, the active metabolite of psilocybin, has been reported to induce changes in neuroplasticity, including neurogenesis, that were accompanied by extinction of conditioned fear-related behaviors [6, 23, 24].”
Comparing psychedelic and meditation experience reports with natural language processing
Kallio-Mannila, K., Salmela, R., & Jylkkä, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-27724-0 · Cited by 4
“Even though some researchers have argued that personally meaningful experiences can be qualitatively similar across multiple substances with different mechanisms of action 1,9,13,14 , it would be optimal to have data where the groups were more homogeneous.”
Neurobiologische Grundlagen der Wirkung von Psychedelika
Vollenweider, F. X., & Preller, K. H. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_70 · Cited by 6
Self-citationNon-ordinary Consciousness for Artificial Intelligence
Montes, G. A. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-63537-8_29 · Cited by 4
Towards a New Materialism in Psychedelic Studies
Oostveen, D. F. (2023) · Deleuze and Guattari Studies · doi:10.3366/dlgs.2023.0530 · Cited by 5
Ketamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
Lehmann, M., Neumann, C., Wasserthal, S., Delis, A., Schultz, J., Hurlemann, R., & Ettinger, U. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113925 · Cited by 5
Addiction to Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”
Farré, M., Galindo, L., & Torrens, M. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_27 · Cited by 4
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.16.431276 · Cited by 4
“The activation of 5-HT2A receptors and induction of a psychedelic state is widely suggested to promote neuroplasticity, which is theorised to be important for psilocybin’s therapeutic efficacy (Vollenweider & Kometer, 2010).”
BackgroundBoltaev, U., Park, H. W., Brown, K. R., Delgado, M., Wu, J., Diaz-Pacheco, B. N., Botero-Pinzon, M., He, K., Ahern, E., Goldshmid, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.04.583022 · Cited by 4
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.